Amgen's office in Russia: building , th floor
Business Address: 123317 Russia, Moscow, Presnenskaya nab. 8, building 1, 7th floor
Phone: 7 (495) 745 0478
Fax: 7 (499) 995 1965
Web: https://www.amgen.ru
| Formerly | Applied Molecular Genetics (1980–1983) |
|---|---|
| Type | Public |
| Traded as |
|
| ISIN | |
| Industry | Biotechnology |
| Founded | April 8, 1980 (1980-04-08) |
| Headquarters | Thousand Oaks, California, U.S. |
| Key people | Robert A. Bradway (Chairman, President, & CEO) |
| Products | Aimovig, Aranesp, Blincyto, Epogen, Kineret, Enbrel, Kyprolis, Neulasta, Neupogen, Nplate, Parsabiv, Prolia, Repatha, Sensipar/Mimpara, Vectibix, Xgeva |
| Revenue |  US$25.424 billion (2020) |
| Operating income |  US$9.672 billion (2019) |
| Net income | US$7.842 billion (2019) |
| Total assets | US$59.707 billion (2019) |
| Total equity | US$9.675 billion (2019) |
| Number of employees | 22,000 (February 2020) |
| Website | amgen.com |
Amgen is one of the world’s leading biotechnology companies. Amgen is a values-based company, deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses. At Amgen, we believe in a “biology first” approach. We use cutting-edge science and technology to study the subtlest biological mechanisms in search of therapies that will improve the lives of those who suffer from serious diseases. Amgen believes the cure for disease can be found inside each and every one of us.